David A. Rinaldi
Naval Medical Center San Diego · 40 works · 2,327 citations · h-index 21
Top works
- Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
- Phase III Comparison of Two Irinotecan Dosing Regimens in Second-Line Therapy of Metastatic Colorectal Cancer
- Multicenter, Randomized Trial for Stage IIIB or IV Non–Small-Cell Lung Cancer Using Weekly Paclitaxel and Carboplatin Followed by Maintenance Weekly Paclitaxel or Observation
- A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation
- Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation.
- Phase I and Pharmacokinetic Study of Temozolomide on a Daily-for-5-Days Schedule in Patients With Advanced Solid Malignancies
- Randomized, Phase III Study of Weekly Paclitaxel in Combination With Carboplatin Versus Standard Every-3-Weeks Administration of Carboplatin and Paclitaxel for Patients With Previously Untreated Advanced Non–Small-Cell Lung Cancer
- Preoperative Therapy with Concurrent Paclitaxel/Carboplatin/Infusional 5-FU and Radiation Therapy in Locoregional Esophageal Cancer
- Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors
- Peripheral neuropathy secondary to docetaxel (Taxotere)
- A Bioavailability and Pharmacokinetic Study of Oral and Intravenous Hydroxyurea
- Phase II Trial of Docetaxel for Cholangiocarcinoma
- Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks
- A phase I trial of topical topitriol (calcitriol, 1,25-dihydroxyvitamin D3) to prevent chemotherapy-induced alopecia
- A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium
- An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer
- Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3‐weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer
- Treatment of Elderly Non–small Cell Lung Cancer Patients with Three Different Schedules of Weekly Paclitaxel in Combination with Carboplatin: Subanalysis of a Randomized Trial
- A multicenter, phase III randomized trial for stage IIIB/IV NSCLC of weekly paclitaxel and carboplatin vs. standard paclitaxel and carboplatin given every three weeks, followed by weekly paclitaxel
- Randomized double-blind phase 2 study evaluating sameday vs next-day administration of pegfilgrastim with docetaxel, doxorubicin, and cyclophosphamide (tac) in women with early stage and advanced breast cancer